Neuropathologic lesions in dogs after prolonged administration of phenylisopropylhydrazine (JB 516) and phenylisobutylhydrazine (JB 835).
HIGHMAN
B
B
MALING
H M
HM
D000818:Animals; D002490:Central Nervous System / Q000473:pathology*; D004285:Dogs; D006834:Hydrazines / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009461:Neurologic Manifestations; D010659:Phenylhydrazines
D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D010659:Phenylhydrazines; C005433:methylphenylpropylhydrazine; C047131:phenylisobutylhydrazine; C084776:pheniprazine
CENTRAL NERVOUS SYSTEM/pathology; HYDRAZINES/pharmacology; MONOAMINE OXIDASE INHIBITORS/pharmacology; NEUROLOGIC MANIFESTATIONS/experimental